



Effective Date: 7/01/2021
Last P&T Approval/Version: 07/2022
Next Review Date: 07/2023
Policy Number: C22067-A

Dupixent (dupilumab) Illinois Medicaid Only

PRODUCTS AFFECTED

Dupixent (dupilumab)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive

DIAGNOSIS:

Asthma, Nasal Polyps, Atopic Dermatitis, Eosinophilic esophagitis

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label along with state and federal requirements, benefits being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review.

A. Asthma

1. Provider attestation that member has a diagnosis of moderate to severe asthma with ONE of the following:
 - a. Eosinophils greater than or equal to 150 cells/microliter with at least one (1) exacerbation requiring an oral corticosteroid burst, ER visit, hospitalization or office visit
OR
 - b. Member is oral corticosteroid dependent
OR

Drug and Biologic Coverage Criteria

- c. Member has a baseline Forced Expiratory Volume (FEV1) that is less than 80% predicted for adults or less than 90% for adolescents
AND
 2. Member has had a trial and failure of ONE of the following:
 - a. Leukotriene modifier
OR
 - b. Medium-High (or maximally tolerated) inhaled corticosteroid (ICS) plus an additional controller medication
OR
 - c. Maximally tolerated ICS/LABA combination
- B. Nasal Polyps
1. Documentation that member has a confirmed diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)
AND
 2. Documentation that member's CRSwNP has been inadequately controlled by medical therapy with two (2) of the following:
Note to reviewer: Prior nasal surgery should be taken into consideration.
 - a. Intranasal Corticosteroids
Note to reviewer: Look back for up to one year for intranasal corticosteroid use.
OR
 - b. Systemic corticosteroids or contraindication or intolerance to systemic corticosteroids
OR
 - c. Nasal nebulized solution of budesonide
- C. Atopic Dermatitis
1. Prescriber attestation to a diagnosis of moderate to severe atopic dermatitis
AND
 2. Documentation that member has had a trial and inadequate response to a medium to high potency topical corticosteroid AND one (1) of the following:
 - a. Generic immunosuppressant
OR
 - b. Topical calcineurin inhibitor
OR
 - c. Phototherapy
OR
 - d. Phosphodiesterase-4 inhibitor (PDE-4)
Note to reviewer: Look back for up to one year for topical corticosteroid use and up to two years for additional agent.
- D. Eosinophilic Esophagitis
1. Prescriber attestation to a diagnosis of eosinophilic esophagitis
AND
 2. Weight is greater than or equal to 40 kg
AND
 3. Documentation that member has tried and failed or had an inadequate response to dietary therapy
AND
 4. Documentation that members has had a trial and inadequate response to a proton pump inhibitor for a minimum of 8 weeks
Note to reviewer: Look back for up to one year for proton pump inhibitor use.

Drug and Biologic Coverage Criteria

CONTINUATION OF THERAPY:

A. ALL INDICATIONS:

1. Prescriber attestation of positive response to therapy

DURATION OF APPROVAL:

Initial authorization: 12 months, Continuation of Therapy: 12 months

PRESCRIBER REQUIREMENTS:

Asthma: Prescribed by or in consultation with a pulmonologist, allergist, or immunologist

Nasal Polyposis: Prescribed by or in consultation with, an allergist, pulmonologist, or otolaryngologist (ENT)

Atopic Dermatitis: None

Eosinophilic esophagitis: Prescribed by or in consultation with a gastroenterologist

AGE RESTRICTIONS:

Atopic Dermatitis: Age 6 months of age and older

Asthma: Age 6 years of age and older

Eosinophilic esophagitis: 12 years of age and older

Nasal Polyposis: Age 18 and older

QUANTITY: See Illinois Medicaid Drug Formulary or use maximum quantity per FDA label

PLACE OF ADMINISTRATION:

The recommendation is that injectable medications in this policy will be for pharmacy benefit coverage and patient self-administered.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Subcutaneous

DRUG CLASS:

Atopic Dermatitis - Monoclonal Antibodies

FDA-APPROVED USES:

DUPIXENT (dupilumab): is an interleukin-4 receptor alpha antagonist indicated:

- For the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.
- As an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
- As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
- For the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40kg, with eosinophilic esophagitis.

Limitations of Use Not for the relief of acute bronchospasm or status asthmaticus

COMPENDIAL APPROVED OFF-LABELED USES:

None

APPENDIX

None

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

None

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of Dupixent (dupilumab) are considered experimental/investigational and therefore, will follow Molina's Off- Label policy. Contraindications to Dupixent (dupilumab) include known hypersensitivity to DUPIXENT or any of its excipients.

OTHER SPECIAL CONSIDERATIONS:

None

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCPSC CODE	DESCRIPTION
NA	n/a

AVAILABLE DOSAGE FORMS:

Dupixent SOSY 100MG/0.67ML
 Dupixent SOPN 200MG/1.14ML
 Dupixent SOPN 300MG/2ML
 Dupixent SOSY 200MG/1.14ML
 Dupixent SOSY 300MG/2ML

REFERENCES

1. Illinois HFS Drugs with Stipulated PA Language per Contract for MCOs 10/01/2021
2. Illinois Medicaid Preferred Drug List, Effective July 1, 2022
3. Dupixent (dupilumab) [prescribing information], Tarrytown, NY: Regeneron Pharmaceuticals, Inc., June 2022